favipiravir profile

favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	492405
CHEMBL ID	221722
CHEBI ID	134722
SCHEMBL ID	587913
SCHEMBL ID	15157866
MeSH ID	M0434732

Synonym
HY-14768
T 705,CAS;259793-96-9
favipiravir; t-705
6-fluoro-3-hydroxy-pyrazine-2-carboxamide
favipiravir
2-pyrazinecarboxamide, 6-fluoro-3-hydroxy-
t-705
CHEBI:134722 ,
CHEMBL221722
avigan
AKOS005166863
favipiravir (jan/usan/inn)
D09537
259793-96-9
avigan (tn)
5-fluoro-2-oxo-1h-pyrazine-3-carboxamide
6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide
A25520
6-fluoro-3-hydroxypyrazine-2-carboxamide
6-fluoro-3-hydroxy-2-pyrazinecarboxamide
t-705 cpd
ew5gl2x7e0 ,
favipiravir [usan:inn:jan]
t 705
unii-ew5gl2x7e0
t705
AKOS015995178
CS-0612
FT-0686297
BCPP000056
PB25591
favipiravir [inn]
favipiravir [who-dd]
favipiravir [jan]
favipiravir [usan]
favipiravir [mi]
AM20080851
S7975
SCHEMBL587913
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
favipiravir (t-705)
SCHEMBL15157866
pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-
AC-28900
6-fluoro-3,4-dihydro-3-oxo-pyrazinecarboxamide
J-518718
6-fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide
mfcd12032148
gtpl11139
BBL104098
favilavir
DB12466
fapilavir
STL557913
FT-0701282
EX-A2285
BCP02422
Q16934561
MS-20791
CCG-266269
NCGC00373041-03
NCGC00373041-06
SY110833
DTXSID60948878
A902150
6-fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide; 6-fluoro-3,4-dihydro-3-oxo-pyrazinecarboxamide; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; favipiravir; t 705; t 705 (pharmaceutical)
PB42412
EN300-1601539
6-fluoro-3-hydroxypyrazine-2-carbo xamide
j05ax27
areplivir
avipiravir
favipiravirum
favipira
avifavir
Z1255381648

Excerpt	Reference	Relevance
"Favipiravir is an antiviral that is being evaluated for the treatment of COVID-19. "	( Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. Doi, Y; Iwasaki, H; Koseki, T; Mizuno, T; Nakajima, K; Takahashi, K; Yamada, S, 2022)	2.43
"Favipiravir is a promising antiviral agent that has been recently approved for treatment of COVID-19 infection. "	( Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma. Abdallah, IA; Bedair, A; Hammad, SF; Mansour, FR, 2022)	2.39
"Favipiravir (FPV) is an orally administrable antiviral drug that selectively inhibits RNA-dependent RNA polymerase and has been repurposed for COVID-19 treatment. "	( Favipiravir in Kidney Transplant Recipients With COVID-19: A Romanian Case Series. Antal, O; Cismaru, C; Elec, AD; Elec, FI; Lupșe, M; Moisoiu, T; Muntean, A, )	3.02
"Favipiravir is a potential antiviral drug undergoing clinical trials to manage various viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). "	( Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Adhikari, A; Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE; Dey, A; Hetta, HF; Moubarak, M; Rauf, A; Shaheen, HM; Usman, IM; Zakariya, AM, 2022)	3.61
"Favipiravir is a selective RNA polymerase inhibitor and a broad-spectrum antiviral drug, an important agent used in viral infections, including Ebola, Lassa, and COVID-19. "	( Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach. Atçalı, T; Caglayan, C; Kandemir, FM; Kara, A; Ulucan, A; Yakut, S, 2023)	2.62
"Favipiravir is a nucleoside analogue that inhibits the replication and transcription of a broad spectrum of RNA viruses, including pathogenic arenaviruses. "	( Potential and action mechanism of favipiravir as an antiviral against Junin virus. Abe, H; Afowowe, TO; Urata, S; Yasuda, J; Zadeh, VR, 2022)	2.44
"Favipiravir is a drug which shows antiviral activity by inhibiting RNA-dependent RNA polymerase. "	( Effect of low and high dose of favipiravir on ovarian and reproductive function in female rats: Biochemical and histopathological evaluation. Akbaş, N; Altındağ, F; Balcı, S; Bulut, S; Çöllüoğlu, Ç; Süleyman, H; Yavuzer, B, 2022)	2.45
"Favipiravir is an approved orally administered antiviral drug that selectively inhibits RNA-dependent RNA polymerase, used off-label to treat COVID-19."	( Favipiravir Efficacy And Safety For The Treatment Of Severe Coronavirus Disease 2019: A Retrospective Study. Abdelmoaty, AS; Abdulrahman, B; Aletreby, W; Alharthy, A; Alhazmi, A; Ali, N; Haddad, M; Hafeez, MM; Kuhail, A; Mady, A; Mhawish, H; Noor, AM; Odat, MA; Rana, MA; Tayar, AA, )	2.3
"Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. "	( Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation. Badr, KA; Bendas, ER; Rezk, MR, 2023)	2.6
"Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease. "	( When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study. Al Sulaiman, K; Alenazi, AA; AlFaifi, M; Alghamdi, YS; Alghwainm, MM; Alhajaji, R; Alharbi, A; Alharbi, R; Aljuhani, O; Almagthali, A; Almutairi, JM; Alonazi, SH; Alotaibi, S; Alotaibi, SM; Altebainawi, AF; Kahtani, K; Korayem, GB; Nahari, M; Thabit, AK; Vishwakarma, R, 2023)	2.62
"Favipiravir is an important selective antiviral against RNA-based viruses, and currently, it is being repurposed as a potential drug for the treatment of COVID-19. "	( Tautomerism and Rotamerism of Favipiravir and Halogenated Analogues in Solution and in the Solid State. Álvarez, G; Cabrera, G; Cerecetto, H; Couto, M; Echeverría, G; Fuentes, G; Gotopo, L; Pezaroglo, H; Piro, O; Romero, AH; Suescun, L, 2023)	2.64
"Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available."	( Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Daikoku, T; Shiraki, K, 2020)	2.72
"Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase, it has been used for treatment of some life-threatening infections such as Ebola virus, Lassa virus and rabies."	( The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled Li, J; Wang, G; Wu, Z; Zhang, C; Zhao, H, 2020)	1.47
"Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. "	( A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Banno, S; Doi, Y; Hase, R; Hibino, M; Hirose, M; Homma, Y; Horiguchi, T; Ikeda, N; Imai, T; Iwata, M; Kabata, D; Kamio, T; Kasahara, H; Kasamatsu, Y; Kashizaki, F; Kato, H; Kato, Y; Kita, T; Koba, H; Kodama, N; Kondo, M; Koseki, T; Lim, CK; Maeki, T; Matsuyama, A; Miyata, M; Mutoh, Y; Nakagawa, A; Nakatsumi, H; Nakayama, E; Ogawa, T; Saijo, M; Shinoda, M; Shintani, A; Tajima, S; Taniguchi, S; Terada, M; Teramachi, M; Uchida, Y; Yamamoto, M; Yokota, K; Yokoyama, T; Yoshida, H; Yoshida, J; Yuzawa, Y, 2020)	2.24
"Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA."	( Favipiravir and COVID-19: A Simplified Summary. Ghasemnejad-Berenji, M; Pashapour, S, 2021)	2.79
"Favipiravir is an antiviral drug that is expected to have a therapeutic effect on SARS-CoV2 infection. "	( Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. Igari, H; Ishii, I; Nakada, TA; Sayama, M; Suzuki, T; Yamazaki, S, 2021)	2.32
"Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295."	( Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Abd-Elsalam, S; Badawi, R; Dabbous, HM; Ebeid, FFS; El Ghafar, MSA; El-Sayed, MH; Elbahnasawy, M; Sherief, AF; Soliman, S; Tageldin, MA, 2021)	1.72
"Favipiravir is a repurposed antiviral agent in treatment of SARS-CoV-2 infection, and to meet the current need, pharmaceutical companies are working for manufacturing licensed generic favipiravir."	( Bioequivalence study of two favipiravir tablet formulations in healthy male subjects. Aytaç, P; Demiray, G; Doğan-Kurtoğlu, E; Erenmemişoğlu, A; Güney, B; Nacak, M; Ozbek, M; Sağlam, O; Saraner, N; Sevici, G; Ulusoy, MG, 2021)	1.64
"Favipiravir is an established antiviral that is currently being assessed as an investigational drug for the treatment of COVID-19. "	( Plain Achanta, PS; Chen, SN; Pauli, GF, 2021)	2.06
"Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients."	( Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA, 2021)	1.65
"Favipiravir is a repurposed drug to treat coronavirus 2019 (COVID-19). "	( Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Abraham, I; Al-Jedai, A; Alajami, HN; Alali, AH; Alamer, A; Alfaifi, M; AlHassar, F; Alkharji, F; Almulhim, AS; Almutairi, M; Almutairi, W; Alosaimi, B; Alrashed, AA; Alsaeed, A; Baredhwan, AA; Howaidi, J; Mohzari, Y; Sulaiman, T, 2021)	2.36
"Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. "	( Favipiravir-resistant influenza A virus shows potential for transmission. Akinbami, O; Barclay, WS; Frise, R; Galiano, M; Gallego Cortés, A; Goldhill, DH; Lackenby, A; Miah, S; Shelley, J; Yan, A; Zambon, M; Zhou, J, 2021)	3.51
"Favipiravir (FAV) is an antiviral drug that is currently in clinical trials for use against COVID-19."	( Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation. Ali, MK; Goto, M; Moniruzzaman, M; Moshikur, RM; Wakabayashi, R, 2021)	2.79
"Favipiravir is an antiviral agent that is recently used for SARS-CoV2 infection. "	( A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Demir, B; Demir, E; Sütcüoğlu, O; Ünsal, O; Yazıcı, O, 2022)	2.45
"Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). "	( Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report. Chiba, N; Hata, M; Hidaka, S; Imai, T; Kikuchi, N; Sakurai, A; Sekimoto, M, 2022)	2.4
"Favipiravir is a broad-spectrum inhibitor of viral RNA-dependent RNA polymerase (RdRp) currently being used to manage COVID-19. "	( Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. Dandapat, J; Padhi, AK; Saudagar, P; Tripathi, T; Uversky, VN, 2021)	2.35
"Favipiravir (T-705) is a broad-spectrum antiviral agent that has been approved in Japan for the treatment of influenza virus infections. "	( Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. Abdelnabi, R; Beaucourt, S; Blanc, H; Canard, B; Delang, L; Froeyen, M; Imbert, I; Leyssen, P; Morais, ATS; Neyts, J; Vignuzzi, M, 2017)	2.13
"Favipiravir is an antiviral agent effective against several RNA viruses. "	( Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis. Domingo, E; Escribano-Romero, E; Jiménez de Oya, N; Saiz, JC, 2017)	2.18
"Favipiravir is an antiviral drug that acts by increasing the genome-wide mutation rate of influenza A virus (IAV)."	( The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution. Bank, C; Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Liu, P; Matuszewski, S; Ormond, L; Renzette, N; Wang, JP; Zeldovich, K, 2017)	1.45
"Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. "	( Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM, 2018)	2.25
"Favipiravir is a broad-spectrum antiviral agent that has demonstrated efficacy against Ebola virus (EBOV) in rodents. "	( Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Bavari, S; Bixler, SL; Bocan, TM; Cazares, LH; Dong, L; Donnelly, G; Epstein, C; Garza, NL; Giesing, D; Koistinen, KA; Lenk, R; Liang, LF; Nuss, J; Soloveva, V; Van Tongeren, SA; Warren, TK; Welch, L; Wells, J; Wetzel, KS, 2018)	2.3
"Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe."	( Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Dawes, BE; Freiberg, AN; Furuta, Y; Ikegami, T; Juelich, T; Kalveram, B; Komeno, T; Lee, B; Park, A; Smith, JK; Zhang, L, 2018)	2.64
"Favipiravir (FAV) is a viral polymerase inhibitor with broad-spectrum activity."	( Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Brown, AN; Bulitta, JB; Kaushik, A; Kim, TH; Pires de Mello, CP; Tao, X; Vicchiarelli, M, 2018)	1.52
"Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. "	( The mechanism of resistance to favipiravir in influenza. Barclay, WS; Fletcher, RA; Goldhill, DH; Lackenby, A; Langat, P; Te Velthuis, AJW; Zambon, M, 2018)	2.21
"Favipiravir is a broad-spectrum antiviral drug that may be used to treat influenza. "	( Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. Barclay, WS; Galiano, M; Goldhill, DH; Kellam, P; Lackenby, A; Langat, P; Miah, S; Xie, H; Zambon, M, 2019)	2.24
"Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever."	( Favipiravir: a new medication for the Ebola virus disease pandemic. Hasegawa, M; Ishii, M; Lefor, AK; Nagata, T, 2015)	2.58
"Favipiravir (T-705) is a new anti-influenza drug approved for human use in Japan and progressing through Phase 3 clinical trials in the U.S. "	( Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Furuta, Y; Gowen, BB; Hagloch, J; Hall, JO; Sefing, EJ; Smee, DF; Westover, JB, 2015)	2.21
"Favipiravir (T-705) is a new antiviral drug with strong inhibitory activity on RNA-dependent RNA polymerase of most RNA virus genome. "	( [Favipiravir, a new concept of antiviral drug against influenza viruses]. Reina, J; Reina, N, 2017)	2.81

Excerpt	Reference	Relevance
"Favipiravir has a wide range of activity against many single-stranded RNA viruses, is well tolerated in humans and has a high barrier to resistance."	( A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Farhadi, T; Hashemian, SM; Velayati, AA, 2021)	1.72
"Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. "	( In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Deyde, VM; Furuta, Y; Gubareva, LV; Klimov, AI; Mishin, VP; Sleeman, K, 2010)	2.09
"Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. "	( Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19. Punyaratabandhu, P; Vanitchpongphan, S, 2022)	3.61
"Favipiravir has shown promising results for COVID-19 globally. "	( Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals. Ansari, A; Barkate, H; Bhagat, S; Dhar, R; Lakhe, M; Panchal, S; Patil, S; Talwar, D; Tiwaskar, M, 2022)	2.46
"Favipiravir has been developed as an anti-influenza agent, and this agent may be effective against these viruses in vitro."	( Detailed Analyses of Molecular Interactions between Favipiravir and RNA Viruses In Silico. Ishii, H; Kimura, H; Kurai, D; Sada, M; Saraya, T; Shirai, T; Sunagawa, S, 2022)	1.69
"Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. "	( Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Abdulrahim, Z; Abdulrahman, A; Aljawder, D; Almahroos, A; Alnashaba, F; AlQahtani, M; Alsahaf, F; Alshaikh, F; Atkin, SL; Fayyad, MA; Kumar, N; Mohamed, MW; Otoom, S; Saeed, S, 2022)	2.45
"Favipiravir and Meropenem have been concurrently used as directly acting antiviral and antibiotic agents for the treatment of coronavirus disease in human plasma. "	( Sensitive and selective bioscreening of the most commonly used coronavirus disease drug, Favipiravir, and its co-administered therapeutic, Meropenem, in human plasma. Abdelaleem, EA; Abdelfatah, RM; Abdelmoety, RH; Abdelmomen, EH; Emam, AA, 2022)	2.39
"Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. "	( Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Daikoku, T; Shiraki, K, 2020)	3.44
"Favipiravir (T-705) has been shown to have in vitro anti-viral activity against a broad range of positive and negative strand RNA viruses."	( In vitro inhibition of mumps virus replication by favipiravir (T-705). Hickman, CJ; Latner, DR; Lawson, B; Rota, PA; Suppiah, S, 2020)	1.53
"Favipiravir has a wide range of activity against many single-stranded RNA viruses, is well tolerated in humans and has a high barrier to resistance."	( A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Farhadi, T; Hashemian, SM; Velayati, AA, 2021)	1.72
"Favipiravir has resulted in a higher viral clearance than remdesivir."	( A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021)	1.34
"Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models."	( A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. Azuma, T; Furumoto, A; Haku, T; Hidaka, M; Himeji, D; Ikeda, K; Ishida, M; Ishimaru, T; Kadowaki, N; Kakihana, Y; Kamikokuryo, C; Kaneko, M; Kawamura, M; Kurosu, T; Ohge, H; Saijo, M; Sakabe, S; Shimojima, M; Suemori, K; Takahashi, T; Takenaka, K; Taniguchi, T; Yamanaka, A; Yasukawa, M; Yoshikawa, T, 2021)	1.55
"Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about teratogenicity and pill burden, and an unknown optimal dose. "	( Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR, 2021)	2.31
"Favipiravir (T-705) has been developed as a potent anti-influenza drug and exhibited a strong inhibition effect against a broad spectrum of RNA viruses. "	( The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription. Cheung, PP; Chong, TH; Huang, X; Wang, Y; Xu, X; Yuan, C; Zhang, L, 2021)	2.06
"Favipiravir has already been used off-label to treat patients infected with the Ebola virus and the Lassa virus."	( Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Abdelnabi, R; Delang, L; Neyts, J, 2018)	2.64
"Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order."	( Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Dawes, BE; Freiberg, AN; Furuta, Y; Ikegami, T; Juelich, T; Kalveram, B; Komeno, T; Lee, B; Park, A; Smith, JK; Zhang, L, 2018)	2.64
"Favipiravir or T-705 has broad antiviral activity and has already undergone phase II and is undergoing phase III clinical trials for influenza."	( Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Eastaugh, LS; Lenk, RP; Lever, MS; Nelson, M; Smither, SJ; Steward, JA, 2014)	1.39
"Favipiravir (T-705) has demonstrated potent antiviral activity against multiple RNA virus families and is presently in clinical evaluation for the treatment of influenza."	( Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Fouchier, RA; Jochmans, D; Neyts, J; Smits, SL; van den Hoogen, BG; van Nieuwkoop, S, 2016)	1.47

Excerpt	Reference	Relevance
"Favipiravir caused an increase in malondialdehyde (MDA), nuclear factor kappa B (NF-κB) and interleukin 6 (IL-6) levels in the liver tissue, as well as elevated alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) levels in the blood. "	( Favipiravir-induced inflammatory and hydropic degenerative liver injury in rats. Altindag, F; Altuner, D; Bilici, S; Bulut, S; Gulaboglu, M; Gursul, C; Ozcicek, A; Sarigul, C; Suleyman, H; Suleyman, Z, 2023)	3.8
"Favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and its sequential use may cause hepatotoxicity in this case. "	( A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Demir, B; Demir, E; Sütcüoğlu, O; Ünsal, O; Yazıcı, O, 2022)	2.45

Excerpt	Reference	Relevance
"The favipiravir-treated and hydroxychloroquine-treated group showed increased viral clearance (OR, 95%CI 2.38, 0.83-6.78, OR, 95%CI 2.15, 0.78-5.92, respectively) compared to standard care, but this was not significant."	( Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Abdulrahim, Z; Abdulrahman, A; Aljawder, D; Almahroos, A; Alnashaba, F; AlQahtani, M; Alsahaf, F; Alshaikh, F; Atkin, SL; Fayyad, MA; Kumar, N; Mohamed, MW; Otoom, S; Saeed, S, 2022)	1.49
"Favipiravir treatment should be used with caution, especially in women of reproductive age."	( Effect of low and high dose of favipiravir on ovarian and reproductive function in female rats: Biochemical and histopathological evaluation. Akbaş, N; Altındağ, F; Balcı, S; Bulut, S; Çöllüoğlu, Ç; Süleyman, H; Yavuzer, B, 2022)	1.73
"Favipiravir treatment improved survival with pre-symptomatic (days 5-14) and post-symptomatic (days 9-18) treatment."	( Evaluation of a novel severe combined immunodeficiency mouse model for antiviral drug evaluation against Chandipura virus infection. Ebihara, H; Furuta, Y; Kato, H; Kawahara, M; Kitaura, S; Komeno, T; Moriya, K; Nakajima, N; Nakayama, N; Saijo, M; Satoh, M; Suzuki, T; Takayama-Ito, M; Tobiume, M, 2023)	1.63
"Favipiravir treatment protected mice from lethal infection with all viruses tested, whereas oseltamivir treatment did not protect at all."	( Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. Kawaoka, Y; Kiso, M; Yamayoshi, S, 2023)	2.01
"Favipiravir is used in treatment of Covid-19 patients. "	( Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report. Ayıntap, E; Aytogan, H; Doran, MA, 2021)	2.31
"Favipiravir treatment was offered to patients with EVD on a compassionate-use basis."	( Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study. Afrough, B; Akoi Bore, J; Anglaret, X; Arnold, U; Bah, A; Baum, JHJ; Beavogui, AH; Becker-Ziaja, B; Bockholt, S; Böttcher, JP; Cabeza-Cabrerizo, M; Camara, AM; Camino, A; Carroll, MW; Carter, L; Castro, CM; Cisse, SD; Colin, G; Cowley, LA; Di Caro, A; Diallo, B; Drury, P; Duraffour, S; Enkirch, T; Fleischmann, E; Formenty, P; Gabriel, M; Garcia-Dorival, I; Ghebreghiorghis, L; Günther, S; Gurry, C; Hetzelt, N; Hinzmann, J; Holm, T; Hugh Logue, C; Ippolito, G; Jaeger, A; Juchet, S; Kafetzopoulou, L; Keita, S; Kerber, R; Koivogui, L; Kolie, JS; Kosgei, A; Krumkamp, R; Kuisma, E; Lorenz, E; Magassouba, N; Malvy, D; Marchal, CL; May, J; Mazzarelli, A; Meisel, S; Mertens, M; Michel, J; Miranda, O; Nitzsche, K; Pallasch, E; Patrono, LV; Portmann, J; Raymond Koundouno, F; Repits, J; Rickett, NY; Rudolf, M; Sachse, A; Singethan, K; Sissoko, D; Stoecker, K; Vitoriano, I; Wölfel, R; Wurr, S; Yenamaberhan, RL; Zekeng, EG, 2019)	1.5
"Favipiravir treatment resulted in undetectable levels of serum and tissue viral titers and prevented the prominent thrombocytopenia and leucopenia observed in placebo-treated animals during the acute phase of infection."	( Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. Brasel, T; Freiberg, AN; Furuta, Y; Gowen, BB; Hill, TE; Juelich, TL; Pietzsch, C; Sefing, EJ; Smith, JK; Tigabu, B; Yun, T; Zhang, L, 2013)	2.55
"Treatment with favipiravir was shown to reduce the infectivity of Rift Valley fever virus both in cell cultures and in experimental animal models, but the mechanism of this protective effect is not understood."	( Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir. Borrego, B; Brun, A; de Ávila, AI; Domingo, E, 2019)	1.1

Excerpt	Reference	Relevance
" We also show that T-705 is as effective as, and less toxic than, ribavirin, as infected T-705-treated hamsters on average maintain their weight better and recover more rapidly than animals treated with ribavirin."	( Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH, 2008)	0.35
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis."	( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017)	0.46
" Adverse events were observed in 36% of favipiravir and 8% of control patients."	( Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Barkate, H; Caracta, CF; Kadam, J; Patil, S; Pendse, A; Rangwala, S; Singh, P; Tandon, M; Udwadia, ZF; Wu, W, 2021)	1.2
" Regarding adverse effects, except for the occurrence of rash (higher in the FPV group), safety was comparable to SOC."	( Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Bhattacharyya, A; Dhibar, DP; Kaur, H; Medhi, B; Prakash, A; Sarma, P; Semwal, A; Singh, H, )	0.37
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2."	( The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M, 2021)	0.62
" Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs)."	( A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. Azuma, T; Furumoto, A; Haku, T; Hidaka, M; Himeji, D; Ikeda, K; Ishida, M; Ishimaru, T; Kadowaki, N; Kakihana, Y; Kamikokuryo, C; Kaneko, M; Kawamura, M; Kurosu, T; Ohge, H; Saijo, M; Sakabe, S; Shimojima, M; Suemori, K; Takahashi, T; Takenaka, K; Taniguchi, T; Yamanaka, A; Yasukawa, M; Yoshikawa, T, 2021)	0.83
" The scientific community is studying and testing numerous compounds that can be effective and safe for treating people with covid-19."	( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021)	0.62
" No differences for the risk of any adverse events are observed between convalescent plasma and remdesivir compared to standard treatment."	( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021)	0.62
" Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients."	( Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA, 2021)	1.84
" In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation."	( Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G, 2021)	0.62
" Transferred to ICU and adverse events were not statistically different between two groups."	( The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R, 2021)	0.92
" Case fatality rates (CFRs), clinical progress, and adverse effects were compared."	( Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome. Cui, N; Fang, LQ; Li, H; Li, JC; Liu, W; Lu, QB; Lv, SM; Peng, XF; Song, YB; Wang, HQ; Yang, T; Yao, WS; Yuan, C; Yuan, Y; Zhang, DN; Zhang, XA; Zhao, J, 2021)	0.88
"FPV was safe in treating SFTS patients but showed no benefit for those aged >70 years."	( Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome. Cui, N; Fang, LQ; Li, H; Li, JC; Liu, W; Lu, QB; Lv, SM; Peng, XF; Song, YB; Wang, HQ; Yang, T; Yao, WS; Yuan, C; Yuan, Y; Zhang, DN; Zhang, XA; Zhao, J, 2021)	0.88
" ICU admission, length of stay (LOS) in hospital, in-hospital mortality, and the incidence of adverse events were also measured."	( Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial. Bazram, A; Farshidi, H; Fathalipour, M; Gharibzadeh, A; Hassaniazad, M; Khalili, E; Noormandi, A, 2022)	1.03
"This study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19."	( The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Abdelaal, AH; Abozaid, AA; Ads, AM; Alhijazeen, S; Aziz, JMA; Ghula, S; Hirayama, K; Hung, DT; Huy, NT; Ibrahim, AM; Iiyama, T; Karmally, Z; Kita, K; Kouz, B; Le, TN; Makram, AM; Nakhare, S; Nam, NH; Pancharatnam, RA; Phuong, NQ; Shabouk, MB; Tawfik, GM; Turnage, M, 2022)	1.23
" Regarding adverse events, favipiravir groups had higher rates of hyperuricemia (RR = 9."	( The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Abdelaal, AH; Abozaid, AA; Ads, AM; Alhijazeen, S; Aziz, JMA; Ghula, S; Hirayama, K; Hung, DT; Huy, NT; Ibrahim, AM; Iiyama, T; Karmally, Z; Kita, K; Kouz, B; Le, TN; Makram, AM; Nakhare, S; Nam, NH; Pancharatnam, RA; Phuong, NQ; Shabouk, MB; Tawfik, GM; Turnage, M, 2022)	1.29
" The most common side effect was liver dysfunction, in 26 (7."	( Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study. Ergür, FÖ; Kavurgacı, S; Ozturk, A; Şener, MU; Yıldız, M, )	0.41
" Characteristics of all participants and profiles of adverse events (AEs) were collected and analyzed."	( The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study. Hayashi, T; Igarashi, T; Nakamura, T; Ohyama, Y; Saito, A; Saito, E; Suga, H; Sumiyoshi, H; Takara, K; Tokue, Y; Tomizawa, S; Yanagisawa, K, 2022)	0.98
" The primary endpoints here considered were any adverse events observed or reported during the treatment cycle with estimates of odds ratio (OR) and 95% confidence interval (CI), until November 6, 2021."	( A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients. Chen, M; Dai, W; Yang, F; Yang, K; Zeng, J, 2022)	0.94
" Adverse events occurred in 55."	( Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. Abla, N; Arbe-Barnes, S; Chandiwana, N; Chughlay, MF; Dineka, Y; Duparc, S; Francois Venter, WD; Hill, A; Johnstone, H; Ju, C; Kim, B; Kruger, C; Marrast, AC; Miller, R; Owen, A; Windgassen, D, 2022)	0.72

Excerpt	Reference	Relevance
" The present study evaluated the possiblility of a pharmacokinetic interaction between favipiravir and acetaminophen, in vitro and in vivo."	( Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Court, MH; Epstein, CR; Giesing, D; Greenblatt, DJ; Harmatz, JS; Kadota, T; Kurosaki, C; Nakagawa, Y; Nakamura, T; Zhao, Y, 2015)	2.08
" In human volunteers, both acute (1 day) and extended (6 days) administration of favipiravir slightly but significantly increased (by about 20 %) systemic exposure to acetaminophen (total AUC), whereas Cmax was not significantly changed."	( Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Court, MH; Epstein, CR; Giesing, D; Greenblatt, DJ; Harmatz, JS; Kadota, T; Kurosaki, C; Nakagawa, Y; Nakamura, T; Zhao, Y, 2015)	2.09
" Here, we review the pharmacokinetic and pharmacodynamic information presently available for these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in human clinical trials or animal models for pharmacodynamics."	( Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. de Lamballerie, X; Guedj, J; Madelain, V; Mentré, F; Nguyen, TH; Olivo, A; Taburet, AM, 2016)	0.43
" Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen."	( Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. Anglaret, X; Baize, S; Bore, JA; Carazo, S; Carbonnelle, C; Conde, MN; de Lamballerie, X; Gala, JL; Guedj, J; Jacquot, F; Laouénan, C; Madelain, V; Malvy, D; Mentré, F; Nguyen, TH; Pastorino, B; Piorkowski, G; Raoul, H; Rodallec, A; Sissoko, D; Taburet, AM, 2017)	1.9
" Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers."	( Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM, 2018)	0.8
" Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism."	( Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Chen, XP; Du, YX, 2020)	2.24
" Parameter estimates were then combined with a published population pharmacokinetic model in Chinese patients to predict human intracellular FAVI-RTP."	( Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR, 2021)	0.87
" The aqueous solubility and in vivo pharmacokinetic properties of the FAV-ILs were also evaluated."	( Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation. Ali, MK; Goto, M; Moniruzzaman, M; Moshikur, RM; Wakabayashi, R, 2021)	2.06
" In this symposium review, we introduce our pharmacokinetic study of antiviral drugs in patients with COVID-19, focusing on the university-medical institution collaboration."	( [Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19]. Irie, K, 2023)	0.91
" Its pharmacokinetic profile varies depending on ethnic group."	( Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation. Badr, KA; Bendas, ER; Rezk, MR, 2023)	1.15

Excerpt	Reference	Relevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
"We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin."	( Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. Bockholt, S; Günther, S; Krasemann, S; Lüdtke, A; Muñoz-Fontela, C; Oestereich, L; Pallasch, E; Rieger, T; Ruibal, P; Wurr, S, 2016)	1.08
"To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia."	( Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Al Bahrani, M; Al Balushi, Z; Al Barwani, U; Al Lawati, A; Al Naabi, H; Al Salmi, I; Al Sharji, M; Al-Zakwani, I; Ambusaidi, Z; Khamis, F; Pandak, N, 2021)	1.13
" We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19."	( Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Chen, G; Chen, X; Li, J; Qin, Y; Wang, G; Wang, K; Wei, M; Wu, Z; Yu, J; Zhang, C; Zhao, H; Zhu, Q, 2021)	1.15
" Patients were randomly assigned (3:1:1) to a 14-day combination of favipiravir combined with tocilizumab (combination group), favipiravir, and tocilizumab."	( Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Chen, G; Chen, X; Li, J; Qin, Y; Wang, G; Wang, K; Wei, M; Wu, Z; Yu, J; Zhang, C; Zhao, H; Zhu, Q, 2021)	1.16
"Tocilizumab combined with or without favipiravir can effectively improve the pulmonary inflammation of COVID-19 patients and inhibit the deterioration of the disease."	( Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Chen, G; Chen, X; Li, J; Qin, Y; Wang, G; Wang, K; Wei, M; Wu, Z; Yu, J; Zhang, C; Zhao, H; Zhu, Q, 2021)	1.19
" However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19."	( Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021)	0.62
"In this study, the therapeutic efficacy of quercetin in combination with remdesivir and favipiravir, were evaluated in severe hospitalized COVID-19 patients."	( The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. Abolnezhadian, F; Alavi, SM; Ghafourian, M; Khodadadi, A; Mahmoudian-Sani, MR; Nashibi, R; Sharhani, A; Shohan, M, 2022)	0.94
" It was observed that FPV and IBP interact in several ways via hydrogen bonding (HB) leading to changes in the activities of the combined drug and IBP…FPV is predicted to be orally bioavailable."	( Theoretical insights of the drug-drug interaction between favipiravir and ibuprofen: a DFT, QTAIM and drug-likeness investigation. Alver, Ö; Bağlayan, Ö; Parlak, C; Ramasami, P, 2023)	1.15

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Proficient bioavailability coupled with no predicted in silico toxicity rendered them as prospective alternatives for designing and development of novel combinatorial therapy formulations for improving existing treatment regimes to combat COVID-19."	( Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Banerjee, DI; Darji, SA; Lipsa Rath, S; Toor, HG, 2021)	0.62

Excerpt	Relevance	Reference
" Drug dose-response curves confirmed complete drug resistance to oseltamivir, partial sensitivity to peramivir, and retained susceptibility to zanamivir and favipiravir against the A/Hong Kong/2369/2009 virus."	( In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Barnard, DL; Furuta, Y; Hurst, BL; Smee, DF; Tarbet, EB; Vollmer, AH, 2014)	0.92
" Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen."	( Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. Anglaret, X; Baize, S; Bore, JA; Carazo, S; Carbonnelle, C; Conde, MN; de Lamballerie, X; Gala, JL; Guedj, J; Jacquot, F; Laouénan, C; Madelain, V; Malvy, D; Mentré, F; Nguyen, TH; Pastorino, B; Piorkowski, G; Raoul, H; Rodallec, A; Sissoko, D; Taburet, AM, 2017)	1.9
" Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus."	( The path towards effective antivirals against rabies. Jochmans, D; Neyts, J, 2019)	0.51
" Finally, we observed that protection can be achieved in mice down to 8 mg/kg/day, which is lower than the dosing regimens previously reported."	( Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Bavari, S; Bixler, SL; Bocan, TM; Cazares, LH; Donnelly, G; Epstein, C; Garza, NL; Giesing, D; Lenk, R; Liang, LF; Soloveva, V; Van Tongeren, SA; Warren, TK; Welch, L; Wells, J; Wetzel, KS, 2018)	0.73
" While no survival benefit was observed in two studies employing once- or twice-daily oral dosing of favipiravir during EBOV infection of NHPs, an antiviral effect was observed in terms of extended time-to-death and reduced levels of viral RNA."	( Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Bavari, S; Bixler, SL; Bocan, TM; Cazares, LH; Dong, L; Donnelly, G; Epstein, C; Garza, NL; Giesing, D; Koistinen, KA; Lenk, R; Liang, LF; Nuss, J; Soloveva, V; Van Tongeren, SA; Warren, TK; Welch, L; Wells, J; Wetzel, KS, 2018)	1.08
" These levels are higher than those found in the JIKI trial, where patients had median trough drug concentrations equal to 46 and 26 μg/ml at day 2 and day 4 post-treatment, respectively, and suggest that the dosing regimen in the JIKI trial was suboptimal."	( Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. Carbonnelle, C; de Lamballerie, X; Guedj, J; Gunther, S; Jacquot, F; Madelain, V; Mentré, F; Nguyen, THT; Piorkowski, G; Raoul, H; Rodallec, A, 2018)	0.8
" Here we employed the hollow-fiber infection model (HFIM) to simulate the human pharmacokinetic (PK) profiles associated with the clinically utilized FAV dosage regimens against influenza and Ebola viruses and assessed the viral burden profiles."	( Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Brown, AN; Bulitta, JB; Kaushik, A; Kim, TH; Pires de Mello, CP; Tao, X; Vicchiarelli, M, 2018)	0.8
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."	( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020)	0.56
" In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model."	( Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. Anglaret, X; Baize, S; de Lamballerie, X; Graw, F; Guedj, J; Günther, S; Laouénan, C; Madelain, V; Malvy, D; Mentré, F; Nguyen, THT; Oestereich, L; Piorkowski, G; Raoul, H, 2020)	0.98
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."	( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Govil, A; Luckett, K; Miller-Handley, H, 2020)	0.56
" This approach has important assumptions, but indicates that, despite rapid clearance of the parent from plasma, sufficient intracellular FAVI-RTP may be maintained across the dosing interval because of its long intracellular half-life."	( Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR, 2021)	0.87
" They were enquired on- 1) demographics,practice information, 2) place of favipiravir in clinical practice, 3) treatment protocol for mild to moderate COVID-19, 4) dosage and duration of favipiravir, 5) effectiveness of favipiravir, 6) tolerability of favipiravir 7) global efficacy and safety assessment of favipiravir."	( Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals. Ansari, A; Barkate, H; Bhagat, S; Dhar, R; Lakhe, M; Panchal, S; Patil, S; Talwar, D; Tiwaskar, M, 2022)	1.25
"Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at significantly lower concentrations than the plasma trough levels achieved by the dosage adopted for influenza treatment and exhibits efficacy against coronavirus disease 2019 (COVID-19) pneumonia."	( Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. Kaszynski, RH; Matsumoto, S; Sakai, K; Sato, N; Shiraki, K; Takemoto, M, 2022)	2.38
" In multiple logistic regression analysis, the favipiravir dosage (adjusted OR = 1."	( Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir. Hanai, Y; Ishii, Y; Mabuchi, T; Matsuo, K; Miyazaki, T; Nishimura, K; Nishizawa, K; Ohashi, H; Tateda, K; Uekusa, S; Yoshio, T; Yoshizawa, S, 2022)	1.2
" Considering the novel mechanism of favipiravir action, especially in managing viral infections, it is vital to pay more attention to the promised favipiravir hold in the management of SARS-CoV-2, its efficacy, and dosage regimen, and interactions with other drugs."	( Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Adhikari, A; Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE; Dey, A; Hetta, HF; Moubarak, M; Rauf, A; Shaheen, HM; Usman, IM; Zakariya, AM, 2022)	2.44
"This favipiravir dosing regimen demonstrated significant antiviral efficacy but inconsistent illness alleviation in uncomplicated influenza."	( Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. Epstein, C; Hayden, FG; Kang, LL; Lenk, RP; Oldham-Creamer, C; Stonis, L, 2022)	2.68
" The compound was well-tolerated and had favorable pharmacokinetics supporting once-per-day oral dosing in guinea pigs."	( Severe mammarenaviral disease in guinea pigs effectively treated by an orally bioavailable fusion inhibitor, alone or in combination with favipiravir. Bailey, KW; Gantla, VR; Gowen, BB; Henkel, G; Hickerson, BT; McCormack, K; Naik, S; Wandersee, L; Westover, JB, 2022)	0.92
" A rapidly growing number of younger pediatric patients in Thailand necessitated the formulation of favipiravir, the most locally accessible antiviral agent against COVID-19, into a child-friendly dosage form as a safer alternative to a dispersion of crushed tablets in simple syrup."	( Basis to Aid Crisis: Favipiravir Oral Solution for Hospital Compounding During COVID-19 Drug Shortage. Jamnongtanachot, P; Khunvichai, A; Mahanonda, N; Mueannoom, W; Pavitrapok, C; Sra-Ium, S; Tuesuwan, B; Vongsutilers, V; Wongpakdee, K, 2023)	1.45
" In conclusion, the UPLC-MS/MS assay is suitable for quantification of favipiravir over a wide range of dosing regimens, and can easily be adapted to other matrices and species."	( Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC-MS/MS method. Barthelemy, K; Bekegnran, CP; Breuer, J; de Lamballerie, X; Driouich, JS; Giocanti, M; Kreins, AY; Nougairede, A; Solas, C, 2023)	1.43
" The aim of this study was to develop a new, green and simple method for the simultaneous determination of FPV and its acid-induced degradation product (ADP) in its pure and pharmaceutical dosage forms."	( A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product. Abd El-Fattah, MH; El-Sayed, HM; Hassan, SA; Sharaf, YA, 2023)	1.15

Role	Description
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor	A DNA polymerase inhibitor that interferes with the action of a RNA-directed RNA polymerase (EC 2.7.7.48).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
primary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
hydroxypyrazine	Any piperazine carrying one or more hydroxy substituents.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Nsp9 interactions (COVID-19 Disease Map)	83	30

Bioassays (542)

Assay ID	Title	Year	Journal	Article
AID575255	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID733269	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID543907	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as survival of animal at 400 mg/kg/day, po administered twice daily for 8 days started 1 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID543660	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283511	Toxicity in BALB/c mouse assessed as survival at 300 mg/kg/day, po twice daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1820899	Antiviral activity against Influenza A virus A/Virginia/ATCC2/2009(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID369464	Antiviral activity against Sandfly fever Naples virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395682	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Tacaribe virus TRVL11573	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370216	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1471163	Antiviral activity against Ebolavirus E718 infected in Vero E6 cells assessed as effective dose after 6 days by neutral red stain based microscopic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID395694	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369859	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID733268	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID575244	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395975	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1471168	Antiviral activity against Foot-and-mouth disease virus O/JPN/2000 by plaque reduction assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID1717749	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID370219	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575379	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283516	Effect on weight change in BALB/c mouse at 300 mg/kg/day, po twice daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1386764	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID1386759	Antiviral activity against influenza A virus assessed as inhibition of viral replicon activity incubated for 30 hrs by firefly luciferase reporter gene assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID1386767	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID283492	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 60 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395931	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370222	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283503	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 600 mg/kg/day, po administered 4 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575517	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283456	Inhibition of increase in lung weight of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 6 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370213	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1386763	Inhibition of influenza A virus Hong Kong/8/1968(H3N2) neuraminidase at 0.1 to 1000 uM by chemiluminescence based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID395697	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369853	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 100 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395943	Metabolic stability in po dosed mouse assessed as drug remaining after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369470	Antiviral activity against Punta Toro virus Adames assessed as reduction of 1 log10 unit viral titer yields after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575400	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from ATCC assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283474	Toxicity in BALB/c mouse assessed as survival at 30 mg/kg/day, po once daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370224	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 60 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395956	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283443	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395960	Antiviral activity against Poliovirus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370202	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575398	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283477	Effect on weight change in BALB/c mouse at 300 mg/kg/day, po once daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369849	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370194	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575411	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395691	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369474	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 50 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1505498	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID575399	Antiviral activity against Influenza A virus (A/Washington/29/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from ATCC assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283476	Toxicity in BALB/c mouse assessed as survival at 3 mg/kg/day, po once daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369855	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 25 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395714	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369870	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575263	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370221	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543880	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered daily for days started 3 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370231	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 15 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283509	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 600 mg/kg/day, po administered 48 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283507	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 600 mg/kg/day, po administered 24 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395933	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1869552	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay
AID543889	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level in surviving animals at 400 mg/kg/day, po administered 5 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369873	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283464	Toxicity in BALB/c mouse assessed as survival at 300 mg/kg/day, po qid for 5 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283525	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl c	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370198	Toxicity in po dosed C57BL/6 mouse administered twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395699	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395711	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395964	% Compound cleared in virus-infected po dosed mouse after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369863	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395703	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543908	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as survival of animal at 400 mg/kg/day, po administered twice daily for 8 days started 2 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370209	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543668	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 100 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283519	Effect on weight change in BALB/c mouse at 10 mg/kg/day, po twice daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395689	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395932	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283444	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575518	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283466	Toxicity in BALB/c mouse assessed as survival at 33 mg/kg/day, po qid for 5 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283454	Reduction of lung viral titre in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 33 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 1 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1308444	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues.
AID283520	Effect on weight change in BALB/c mouse at 3 mg/kg/day, po twice daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283518	Effect on weight change in BALB/c mouse at 30 mg/kg/day, po twice daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575232	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1717748	Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID392525	Antiviral activity against influenza B virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1505490	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID543887	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level in surviving animals at 400 mg/kg/day, po administered 5 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283472	Toxicity in BALB/c mouse assessed as survival at 300 mg/kg/day, po once daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370235	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575247	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283513	Toxicity in BALB/c mouse assessed as survival at 30 mg/kg/day, po twice daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1505489	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID283488	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 10 mg/kg/day, po once daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cel	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283458	Inhibition of increase in lung weight of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 33 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 6 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543681	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 32 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575407	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1308445	Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues.
AID543659	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369847	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575233	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370191	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543672	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 200 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1418307	Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
AID575516	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1))) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283498	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 72 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575240	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395696	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID733266	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID395679	Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543694	Toxicity in syrian golden hamster assessed as number of animals alive at 400 mg/kg/day, po BID administered for 8 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID543895	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus assessed as weight change in surviving animals at 400 mg/kg/day, po BID administered for 8 days started 5 days post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1845471	Antiviral activity against EBOV infected in Vero E6 cells assessed as reduction in virus titer incubated for 5 days by immunofocus assay	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID369473	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 100 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395706	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369472	Antiviral activity against Sandfly fever Naples virus assessed as reduction of 1 log10 unit viral titer yields after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575395	Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370207	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575231	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575384	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395667	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575258	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1758992	Antiviral activity against Marburgvirus Angola infected in African green monkey Vero cells	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Enantiomeric 4'-truncated 6'-fluoro-3-deazaneplanocin and its 3-bromo derivative: Synthesis and antiviral properties, including Ebola and Marburg.
AID575537	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from ATCC assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283499	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 84 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1600738	Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	l-like 3-deazaneplanocin analogues: Synthesis and antiviral properties.
AID543893	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level in non surviving animals at 400 mg/kg/day, po administered 5 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369874	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 5 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575530	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395973	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395942	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection measured on day 7 of vi	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543897	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus assessed as weight change in non surviving animals at 400 mg/kg/day, po BID administered for 8 days started 5 days post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283523	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 3 mg/kg/day, po twice daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543886	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level in surviving animals at 400 mg/kg/day, po administered 4 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395953	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283451	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 33 mg/kg/day, po qid for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543690	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum survival of animal at 200 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283517	Effect on weight change in BALB/c mouse at 100 mg/kg/day, po twice daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369467	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Rift Valley fever virus MP-12	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543666	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 100 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283522	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po twice daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283504	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po administered 12 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369860	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 25 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575237	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1717812	Antiviral actvity against SARS-CoV2 infected in human assessed as latency time to pyrexia reduction at 1600 mg administered twice on day 1 and 600 mg BID for 7 days	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID283496	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 48 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575524	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575529	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370234	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 15 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395708	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370233	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370193	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543888	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level in surviving animals at 400 mg/kg/day, po administered 4 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575514	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283526	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 30 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl ce	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575401	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283448	Cytotoxicity against MDCK cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395687	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as decrease in survival administered po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395969	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1386766	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID283486	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po once daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl ce	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543902	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 1 day post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369852	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543685	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 100 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395955	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370214	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575251	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283483	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po once daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395700	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1717813	Antiviral actvity against SARS-CoV2 infected in human assessed as latency time to cough relief at 1600 mg administered twice on day 1 and 600 mg BID for 7 days	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID575241	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575235	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575528	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1758993	Selectivity index, ratio of EC50 for antiviral activity against Marburgvirus Angola infected in African green monkey Vero cells to CC50 for African green monkey Vero cells	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Enantiomeric 4'-truncated 6'-fluoro-3-deazaneplanocin and its 3-bromo derivative: Synthesis and antiviral properties, including Ebola and Marburg.
AID370200	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283478	Effect on weight change in BALB/c mouse at 100 mg/kg/day, po once daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395669	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 15 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID733270	Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID575257	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369883	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 5 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543892	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level in non surviving animals at 400 mg/kg/day, po administered 4 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1386762	Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase at 0.1 to 1000 uM by chemiluminescence based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID543894	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus assessed as weight change in surviving animals at 400 mg/kg/day, po BID administered for 8 days started 4 days post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370225	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370211	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543661	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283450	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po qid for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543662	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as reduction in virus yield	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1505500	Prodrug activation in MDCK cells assessed as parent compound remaining at 714 uM after 25 hrs by RP-HPLC-UV analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID575538	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575521	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575534	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from ATCC assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543679	Antiviral activity 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 100 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283453	Reduction of lung viral titre in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 1 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370201	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543669	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as reduction in viral titer in liver at 200 mg/kg/day administered twice daily for 8 days started 6 days post infection by quantitative RT-PCR ana	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283445	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575536	Antiviral activity against Influenza A virus (A/Washington/29/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from ATCC assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283491	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 36 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395701	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575236	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1471166	Antiviral activity against Ebolavirus E718 infected in A129 interferon alpha/beta receptor knockout immunodeficient mouse assessed as survival rate at 150 mg/kg, po administered twice daily for 14 days measured after 2 weeks post last dose relative to con	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID575386	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370218	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1692496	Antiviral activity against nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated for 1 hr followed by viral infection and further replacement of fresh medium containing compound	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	COVID-19: Drug Targets and Potential Treatments.
AID543900	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 4 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369460	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1505492	Cytotoxicity against MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID369876	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283473	Toxicity in BALB/c mouse assessed as survival at 100 mg/kg/day, po once daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575397	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543680	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370227	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395678	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1505528	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID283462	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 33 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575523	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575404	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395944	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID392526	Antiviral activity against Influenza C virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID543904	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 3 day post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1505494	Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1505491	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID395959	Antiviral activity against influenza A virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575253	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543677	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575389	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283527	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 10 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl ce	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575383	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369857	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395967	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283493	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 84 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543905	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 4 day post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395693	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543667	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370204	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395970	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395692	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543689	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as survival of animal at 400 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395971	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283479	Effect on weight change in BALB/c mouse at 30 mg/kg/day, po once daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1505525	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added at > 2 to 8 hrs post infection and measured at 10 hrs post infection by RT-qPCR method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID575124	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575512	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370217	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395704	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369865	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 50 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543879	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered daily for days started 2 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID370203	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395673	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as inhibition of liver damage at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283528	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 3 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cel	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1386765	Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
AID575249	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575382	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575393	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543658	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575252	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1617149	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by measuring ATP level incubated for 24 hrs by ATPlite luminescence assay	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region.
AID575262	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395951	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1717810	Toxicity in human infected with SARS-CoV2 assessed as adverse events at 1600 mg, po administered twice on day 1 and 600 mg BID on day 2 to 14 and measured after 14 days	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID283452	Reduction of lung viral titre in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 1 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395690	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543884	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered daily for days started 5 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1820900	Antiviral activity against Influenza A virus A/California/7/2009(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID369840	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 25 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575532	Antiviral activity against Influenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395671	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543682	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575406	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395936	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369880	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 5 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575535	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1758989	Antiviral activity against Zaire ebola virus infected in African green monkey Vero cells	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Enantiomeric 4'-truncated 6'-fluoro-3-deazaneplanocin and its 3-bromo derivative: Synthesis and antiviral properties, including Ebola and Marburg.
AID395937	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395947	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575531	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1717750	Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID395966	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369475	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 25 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369841	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 75 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283489	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 3 mg/kg/day, po once daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cell	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395954	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1872673	Cytotoxicity against MDCK cells	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Influenza-existing drugs and treatment prospects.
AID733264	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID370220	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543896	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus assessed as weight change in non surviving animals at 400 mg/kg/day, po BID administered for 8 days started 4 days post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1364949	Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID543695	Toxicity in syrian golden hamster assessed as weight change at 400 mg/kg/day, po BID administered for 8 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1847238	Antiviral activity against Ebola virus infected in African green monkey Vero E6 cells assessed as reduction in viral titer infected for 1 hr followed by compound addition and measured after 5 days by immunofocus assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID369843	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 100 mg/kg, po administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370192	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 5 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395672	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 15 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369882	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395668	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395709	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395684	Antiviral activity against Pichinde virus An 4763 assessed as reduction of 1 log10 unit viral titer yields after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575380	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370206	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395958	Toxicity in Pichinde virus An 4763 infected po dosed Syrian golden hamster administered twice daily 72 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1471169	Antiviral activity against Ebola virus Mayinga Zaire 1976 infected in IFNAR-/- C57BL/6 mouse assessed as biochemical correlates of disease at 300 mg/kg, po administered twice daily	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID1637800	Antiviral activity against amantadine-sensitive Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as reduction in early stage viral replication by measuring viral titer at 4 uM measured after 12 hrs by crystal violet stain	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus.
AID543882	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered daily for days started 4 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID392528	Antiviral activity against influenza H2N2 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID575540	Antiviral activity against Influenza A virus (A/Washington/29/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from Mill Hill assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stai	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575526	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1505499	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID369842	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575412	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283465	Toxicity in BALB/c mouse assessed as survival at 100 mg/kg/day, po qid for 5 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369844	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369879	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369872	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID392527	Antiviral activity against influenza H1N1 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID369869	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370190	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283505	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 600 mg/kg/day, po administered 12 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543876	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered daily for days started 1 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1505496	Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID575394	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370195	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 5 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID733265	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID395698	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369868	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as inhibition of liver damage at 200 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543903	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 2 day post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369878	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283515	Toxicity in BALB/c mouse assessed as survival at 3 mg/kg/day, po twice daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395934	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283512	Toxicity in BALB/c mouse assessed as survival at 100 mg/kg/day, po twice daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369461	Antiviral activity against La Crosse virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395961	Antiviral activity against Rhinovirus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283441	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1820902	Antiviral activity against Influenza A virus B/Lee/40(type B) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID395675	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 15 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369468	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Sandfly fever Naples virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369466	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Punta Toro virus Adames	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395695	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283482	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po once daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543883	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered daily for days started 4 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369465	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for La Crosse virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283494	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 24 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370229	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369858	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 100 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395677	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283521	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po twice daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369839	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 50 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369854	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369866	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 25 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543877	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered daily for days started 1 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395949	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1471170	Antiviral activity against Ebola virus Mayinga Zaire 1976 infected in IFNAR-/- C57BL/6 mouse at 300 mg/kg, po administered twice daily measured up to 6 days post infection	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID395665	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575541	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from Mill Hill assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395935	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395952	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543890	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level in non surviving animals at 400 mg/kg/day, po administered 4 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575126	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283500	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 96 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370205	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575403	Antiviral activity against Influenza A virus (A/Washington/29/2009(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543663	Selectivity index, ratio of CC50 for African green monkey vero cells to EC90 for Yellow fever virus 17D	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575405	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1364950	Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID543691	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum survival of animal at 100 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369851	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575525	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283497	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 60 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370208	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575519	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1869553	Therapeutic index, ratio of CC50 for Cytotoxicity against dog MDCK cells to IC50 for Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells
AID369875	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395939	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283524	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl c	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575387	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID370210	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370232	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1717741	Antiviral activity against Zaire Ebola virus infected in African green monkey Vero E6 cells measured after 5 days by immunofocus assay	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID575410	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1))infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283468	Effect on weight change in BALB/c mouse at 300 mg/kg/day, po qid measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283461	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1364948	Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID369478	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 100 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395710	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575402	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 1.6 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543885	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered daily for days started 5 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369871	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370199	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370215	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543891	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level in non surviving animals at 400 mg/kg/day, po administered 5 days post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID369864	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 100 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283508	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po administered 48 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575256	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1471167	Antiviral activity against Ebola virus Mayinga Zaire 1976 infected in IFNAR-/- C57BL/6 mouse assessed as survival at 300 mg/kg, po administered twice daily for 13 days measured after 3 weeks	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID283502	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po administered 4 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283447	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283495	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 36 hrs after infection measured on day 11 relative to carboxymethyl cellulo	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID283481	Effect on weight change in BALB/c mouse at 3 mg/kg/day, po once daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575511	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395688	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370212	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395938	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369477	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 200 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543678	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 200 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395974	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369462	Antiviral activity against Punta Toro virus Adames assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575408	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575248	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283470	Effect on weight change in BALB/c mouse at 33 mg/kg/day, po qid measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575513	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395686	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 60 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395683	Antiviral activity against Junin virus Candid-1 assessed as reduction of 1 log10 unit viral titer yields after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369856	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283460	Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575381	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575390	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369850	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 25 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543657	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 1 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID575409	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 4.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369845	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 25 mg/kg, po administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369848	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 100 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575239	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575522	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543901	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 5 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1903183	Antiviral activity against influenza A virus H5N1 infected in dog MDCK cells assessed as inhibition of viral nucleoprotein vRNA expression level measured after 12 hrs post infection by qRT-PCR analysis	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID575385	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575242	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543906	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 5 day post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1617146	Therapeutic index, ratio of CC50 for dog MDCK cells to IC50 for Influenza A virus (A/Taiwan/1/1986(H1N1))	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region.
AID1881740	Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral infection measured after 48 hrs by qRT-PCR analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID370226	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 60 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575527	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1869550	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability
AID369469	Antiviral activity against La Crosse virus assessed as reduction of 1 log10 unit viral titer yields after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575261	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369476	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 75 mg/kg, po twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1758990	Cytotoxicity against African green monkey Vero cells	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Enantiomeric 4'-truncated 6'-fluoro-3-deazaneplanocin and its 3-bromo derivative: Synthesis and antiviral properties, including Ebola and Marburg.
AID575260	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1505488	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID283442	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370196	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as inhibition of liver damage at 75 mg/kg/day, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID369846	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 75 mg/kg, po administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395681	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Pichinde virus An 4763	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575259	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1505502	Prodrug activation in MDCK cells assessed as T-705-RMP formation at 714 uM after 25 hrs by RP-HPLC-UV analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1533455	Antiviral activity against Ebolavirus infected in mouse assessed as protection against viral infection at 30 mg/kg/day relative to control	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID395702	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 15 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283510	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 600 mg/kg/day, po administered 60 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369463	Antiviral activity against Rift Valley fever virus MP-12 assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283469	Effect on weight change in BALB/c mouse at 100 mg/kg/day, po qid measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575396	Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543664	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1505549	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1617147	Therapeutic index, ratio of CC50 for dog MDCK cells to IC50 for Influenza A virus A/Virginia/3/1975 (H3N2)	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region.
AID283449	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1505493	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID575127	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395685	Antiviral activity against Tacaribe virus TRVL11573 assessed as reduction of 1 log10 unit viral titer yields after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543881	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum AST level at 400 mg/kg/day, po administered daily for days started 3 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283485	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po once daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl ce	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369881	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283506	Effect on survival in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po administered 24 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID543898	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 2 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283446	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1505495	Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID395666	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 15 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395965	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575234	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575539	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283487	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 30 mg/kg/day, po once daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl cel	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1820901	Antiviral activity against Influenza A virus A/Aichi/8/68(H3N2) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID283484	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 3 mg/kg/day, po once daily for 5 days administered 1 hr after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID370223	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395930	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395705	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395941	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1505497	Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID283480	Effect on weight change in BALB/c mouse at 10 mg/kg/day, po once daily for 5 days measured after 18 hrs of final treatment	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1471165	Antiviral activity against Respiratory syncytial virus A2 infected in Hep2 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID370230	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395972	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283457	Inhibition of increase in lung weight of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 100 mg/kg/day, po qid for 5 days administered 1 hr after infection measured on day 6 relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID369471	Antiviral activity against Rift Valley fever virus MP-12 assessed as reduction of 1 log10 unit viral titer yields after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395976	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283514	Toxicity in BALB/c mouse assessed as survival at 10 mg/kg/day, po twice daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575246	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID369877	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 5 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370228	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 15 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395712	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575533	Antiviral activity against Influenza A virus (A/Illinois/10/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 128 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283440	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395968	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575230	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID283475	Toxicity in BALB/c mouse assessed as survival at 10 mg/kg/day, po once daily	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID575243	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1758991	Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for antiviral activity against Ebola virus infected in African green monkey Vero cells	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Enantiomeric 4'-truncated 6'-fluoro-3-deazaneplanocin and its 3-bromo derivative: Synthesis and antiviral properties, including Ebola and Marburg.
AID395948	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575392	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1820898	Antiviral activity against Influenza A virus A/Puerto Rico/8/34(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID283490	Effect on survival of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 24 hrs after infection relative to carboxymethyl cellulose	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1692501	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	COVID-19: Drug Targets and Potential Treatments.
AID575125	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395676	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395674	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as inhibition of liver damage at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575520	Antiviral activity against sInfluenza A virus (A/Washington/29/2009(H1N1)) infected in MDCK cells from ATCC assessed as log reduction in viral titer at 42.7 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543665	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1533451	Antiviral activity against Ebolavirus	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID1717740	Antiviral activity against Zaire Ebola virus infected in IFNAR-/- C57BL/6 mouse assessed as mouse survival at 300 mg/kg, po administered twice daily starting from day 6 post infection until day 13 post infection and measured at the end of 3 weeks	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1471164	Antiviral activity against Ebolavirus assessed as reduction in viral titer	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
AID370197	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as protection against viral infection at 10 mg/kg, po twice daily for 5 to 7 days twice daily administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395962	Antiviral activity against Respiratory syncytial virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575254	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543683	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 400 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1717739	Antiviral actvity against SARS-CoV2 infected in human assessed as improvement rate of chest at 1600 mg, po administered twice on day 1 and 600 mg BID on day 2 to 14 and measured after 14 days by computed tomography	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1505504	Prodrug activation in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as T-705-RMP formation at 714 uM by RP-HPLC-UV analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1820896	Antiviral activity against Influenza A virus A/WSN/33(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.
AID575245	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID543878	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 400 mg/kg/day, po administered daily for days started 2 day post viral challenge	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID543684	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 200 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID283501	Lowering of arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 300 mg/kg/day, po qid for 5 days administered 120 hrs after infection measured on day 11 relative to carboxymethyl cellul	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID395670	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 60 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575413	Antiviral activity against sInfluenza A virus (A/California/04/2009(H1N1))infected in MDCK cells from ATCC assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575378	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575238	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395950	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575388	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1617148	Antiviral activity against Influenza A virus A/Virginia/3/1975 (H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by measuring ATP level incubated for 24 hrs by ATPlite luminescence assay	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region.
AID395940	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575515	Antiviral activity against Influenza A virus (A/Mexico/4604/2009(H1N1)) infected in MDCK cells from Mill Hill assessed as log reduction in viral titer at 14.2 uM after 24 hrs by immunofluorescent assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID575391	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID733267	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID395946	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID543671	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 200 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID543899	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 400 mg/kg/day, po administered twice daily for 8 days started 3 day post viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID395680	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus Candid-1	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575250	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1661954	Binding affinity to Ebola virus glycoprotein assessed as dissociation constant incubated for 20 to 30 mins by microscale thermophoresis	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (2.37)	29.6817
2010's	162 (27.46)	24.3611
2020's	414 (70.17)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	47 (7.77%)	5.53%
Reviews	103 (17.02%)	6.00%
Case Studies	61 (10.08%)	4.05%
Observational	12 (1.98%)	0.25%
Other	382 (63.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (69)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions [NCT04400682]	Phase 1	30 participants (Actual)	Interventional	2020-05-28	Completed
A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19 [NCT04346628]	Phase 2	149 participants (Actual)	Interventional	2020-07-12	Completed
Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19 [NCT04358549]	Phase 2	50 participants (Actual)	Interventional	2020-04-17	Completed
Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea [NCT02329054]	Phase 2	126 participants (Actual)	Interventional	2014-12-31	Completed
Evaluation of Effects, Safety, Viral Load and Antibody Level of Functional Food Dietary Supplement Containing Grape Products in Controlled, Randomized Study Using SARSCoV-2 RT-PCR Positive Covid-19 Patients. [NCT05417997]	Phase 3	71 participants (Actual)	Interventional	2021-05-29	Completed
Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia [NCT04613271]	Phase 3	130 participants (Actual)	Interventional	2020-10-15	Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza [NCT01068912]	Phase 2	530 participants (Actual)	Interventional	2010-02-28	Completed
The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management [NCT04646109]	Phase 3	66 participants (Actual)	Interventional	2020-05-11	Completed
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment [NCT04746183]	Phase 1/Phase 2	600 participants (Anticipated)	Interventional	2020-07-03	Active, not recruiting
Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (Casirivimab and Imdevimab) Versus Standard Antiviral Therapy (Remdesivir and Favipravir) as Antiviral Agent Against Corona Virus 2 Infection in Hospitalized COVID-19 Pa [NCT05502081]	Phase 4	265 participants (Actual)	Interventional	2022-09-02	Completed
A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 Infection [NCT04784559]	Phase 3	205 participants (Actual)	Interventional	2021-06-04	Terminated(stopped due to Sponsor has decided to end the study prematurely based on significant difficulties in the recruitment of patients, despite the implementation of corrective measures that still failed to increase the accrual rate required for a feasible completion.)
Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19 [NCT04542694]	Phase 3	200 participants (Actual)	Interventional	2020-05-21	Completed
Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Favicovir 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions [NCT04406194]	Phase 1	30 participants (Actual)	Interventional	2020-05-14	Completed
Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE) [NCT04918927]	Phase 2	120 participants (Actual)	Interventional	2021-10-12	Completed
An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe [NCT03394209]	Phase 2	34 participants (Actual)	Interventional	2018-02-06	Completed
OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA [NCT05222113]		87 participants (Actual)	Observational	2021-08-01	Completed
An Open-Label, Multicenter, Parallel-Group, Randomized, Phase II/III Study to Evaluate the Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 [NCT04828564]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2021-04-30	Not yet recruiting
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type [NCT04425460]	Phase 3	256 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study - [NCT04600999]	Phase 3	14 participants (Actual)	Interventional	2020-10-07	Completed
Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19 [NCT05185284]	Phase 3	217 participants (Actual)	Interventional	2021-08-11	Completed
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial [NCT04387760]	Phase 2	150 participants (Actual)	Interventional	2020-08-11	Completed
Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial [NCT04818320]	Phase 3	500 participants (Actual)	Interventional	2021-02-16	Completed
An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19 [NCT04434248]	Phase 2/Phase 3	330 participants (Actual)	Interventional	2020-04-23	Active, not recruiting
A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment [NCT04718285]	Phase 2	380 participants (Anticipated)	Interventional	2021-05-15	Recruiting
EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN [NCT06024421]	Phase 1	39 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions [NCT04651959]	Phase 1	30 participants (Actual)	Interventional	2020-11-13	Active, not recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316) [NCT02026349]	Phase 3	860 participants (Actual)	Interventional	2014-01-31	Completed
Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19) [NCT04501783]	Phase 3	168 participants (Actual)	Interventional	2020-05-20	Completed
Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen [NCT02739477]	Phase 2	2 participants (Actual)	Interventional	2016-04-30	Terminated(stopped due to End date of epidemic)
A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19) [NCT05279235]	Phase 3	290 participants (Actual)	Interventional	2022-03-14	Terminated(stopped due to Development strategy adjustment)
The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial [NCT04558463]	Phase 3	100 participants (Anticipated)	Interventional	2020-04-16	Recruiting
Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 [NCT04532931]	Phase 2	192 participants (Actual)	Interventional	2020-09-03	Completed
Efficacy of Favipiravir Against Severe Ebola Virus Disease [NCT02662855]	Phase 2	77 participants (Actual)	Interventional	2014-11-30	Completed
Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia [NCT04319900]	Phase 2/Phase 3	150 participants (Anticipated)	Interventional	2020-03-05	Recruiting
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study [NCT04310228]		150 participants (Anticipated)	Interventional	2020-03-08	Recruiting
A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers [NCT01419457]	Phase 1	36 participants (Actual)	Interventional	2011-08-31	Completed
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) [NCT05041907]	Phase 2	3,000 participants (Anticipated)	Interventional	2021-09-30	Recruiting
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA) [NCT05648448]	Phase 2	250 participants (Anticipated)	Interventional	2023-02-22	Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza [NCT02008344]	Phase 3	1,161 participants (Actual)	Interventional	2013-12-31	Completed
Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza [NCT01728753]	Phase 1/Phase 2	550 participants (Actual)	Interventional	2012-11-30	Completed
A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19 [NCT04727775]		150 participants (Actual)	Observational	2020-12-01	Completed
Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial [NCT04359615]	Phase 4	40 participants (Anticipated)	Interventional	2020-04-20	Not yet recruiting
The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study [NCT04376814]		40 participants (Actual)	Interventional	2020-03-29	Completed
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy [NCT04715360]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2020-12-29	Recruiting
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical Trial [NCT04694612]	Phase 3	676 participants (Anticipated)	Interventional	2021-01-01	Recruiting
UMIT-1 Trial: Favipiravir & Ribavirin Phase IB A Randomised Phase Ib Study to Determine the Phase II Dose and to Evaluate the Safety and Efficacy of Intravenous (IV) Favipiravir & Ribavirin [NCT05940545]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2023-07-12	Recruiting
An ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving Favipiravir [NCT04474457]		1,000 participants (Actual)	Observational	2020-06-11	Active, not recruiting
Efficacy and Safety of Favipiravir in Management of COVID-19 [NCT04349241]	Phase 3	100 participants (Actual)	Interventional	2020-04-18	Completed
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial [NCT04907682]	Phase 2	40 participants (Actual)	Interventional	2021-07-30	Completed
An Open Label Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries, Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Che [NCT04478448]	Phase 1	26 participants (Actual)	Interventional	2020-08-13	Completed
A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients [NCT04529499]	Phase 3	353 participants (Actual)	Interventional	2020-08-22	Terminated(stopped due to Study met pre-defined criteria for futility at interim analysis)
Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Loqular 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions [NCT04407000]	Phase 1	30 participants (Actual)	Interventional	2020-06-23	Completed
Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID) [NCT04448119]	Phase 2	67 participants (Actual)	Interventional	2020-10-16	Terminated(stopped due to Recruitment challenges)
An Investigation of the Efficacy and Safety of Favipiravir in Hospitalized NON- SEVERE COVID-19 Patients - An Open-label Randomized Controlled Multi Center Trial [NCT05014373]	Phase 3	144 participants (Anticipated)	Interventional	2020-10-12	Recruiting
A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe [NCT04373733]	Phase 3	502 participants (Actual)	Interventional	2020-05-01	Completed
A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19 [NCT04392973]		268 participants (Actual)	Interventional	2020-05-21	Completed
The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive [NCT04333589]		210 participants (Anticipated)	Interventional	2020-04-01	Recruiting
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type [NCT04336904]	Phase 3	100 participants (Anticipated)	Interventional	2020-03-25	Active, not recruiting
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Favipiravir-HU Compared to Placebo as add-on Therapy to Standard of Care in Asymptomatic to Mild Severity COVID-19 Patients [NCT04940871]	Phase 2	1 participants (Actual)	Interventional	2021-11-25	Terminated(stopped due to Only one patient was enrolled, who who later withdrew the consent. They decided not to contunie the study.)
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment [NCT04351295]	Phase 2/Phase 3	92 participants (Actual)	Interventional	2020-04-20	Completed
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh [NCT04402203]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2020-05-31	Recruiting
Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment [NCT04981379]	Phase 3	1,120 participants (Actual)	Interventional	2020-11-16	Completed
Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Favir 200 Mg Ft In Comparison With Avigan 200 Mg Ft In Healthy Male Subjects Under Fasting Conditions [NCT04444986]	Phase 1	30 participants (Actual)	Interventional	2020-06-05	Completed
Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19) [NCT04600895]	Phase 3	1,231 participants (Actual)	Interventional	2020-11-30	Completed
An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection [NCT04445467]	Phase 2	190 participants (Actual)	Interventional	2020-07-30	Active, not recruiting
"Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19" [NCT04475991]	Phase 2	19 participants (Actual)	Interventional	2021-07-13	Terminated(stopped due to No more patients complying the selection criteria were available for recruitment)
A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19 [NCT04464408]	Phase 2/Phase 3	231 participants (Actual)	Interventional	2020-07-23	Completed
An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 [NCT04411433]	Phase 3	1,008 participants (Actual)	Interventional	2020-05-08	Active, not recruiting
Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 [NCT04499677]	Phase 2	240 participants (Actual)	Interventional	2020-09-24	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01068912 (1) [back to overview]	Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza
NCT04346628 (6) [back to overview]	Count of Participant With Absence of Development of Any Symptoms
NCT04346628 (6) [back to overview]	Time Until Cessation of Oral Shedding of SARS-CoV-2 Virus
NCT04346628 (6) [back to overview]	Count of Participants With Clinical Worsening of COVID-19 Disease
NCT04346628 (6) [back to overview]	Count of Participants With Development of SARS-CoV-2 Antibodies
NCT04346628 (6) [back to overview]	Sars-CoV-2 Viral Load
NCT04346628 (6) [back to overview]	Time Until Cessation of Symptoms
NCT04358549 (5) [back to overview]	Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmin
NCT04358549 (5) [back to overview]	Time to the National Early Warning Score 2 (NEWS2) of 2 or Less, or Hospital Discharge
NCT04358549 (5) [back to overview]	Time to Viral Clearance
NCT04358549 (5) [back to overview]	Characterize the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmax
NCT04358549 (5) [back to overview]	Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Area Under Curve (AUC 0-24)
NCT04400682 (4) [back to overview]	AUC0-tlast
NCT04400682 (4) [back to overview]	Favipiravir Cmax
NCT04400682 (4) [back to overview]	Tmax of Favipiravir
NCT04400682 (4) [back to overview]	AUC0-inf of Favipiravir
NCT04406194 (4) [back to overview]	Tmax of Favipiravir
NCT04406194 (4) [back to overview]	Cmax of Favipiravir
NCT04406194 (4) [back to overview]	AUC0-tlast of Favipiravir
NCT04406194 (4) [back to overview]	AUC0-inf of Favipiravir
NCT04529499 (2) [back to overview]	Primary Efficacy Endpoint: Time to Resolution of Hypoxia (Stage I)
NCT04529499 (2) [back to overview]	Percentage of Patients Dying (All Cause (Stage I)
NCT04542694 (12) [back to overview]	A Number of Patients With Fever Reduction Below 37.2 ° C by the 3rd Day of Therapy
NCT04542694 (12) [back to overview]	Amount of Patients Without Any Clinical Signs of Disease by the Completion of Therapy (Category 0 According to a WHO Categorical Ordinal Scale)
NCT04542694 (12) [back to overview]	Change in the Level of Lung Damage According to CT
NCT04542694 (12) [back to overview]	Rate of Clinical Status Improvement
NCT04542694 (12) [back to overview]	Rate of the Use of Mechanical Ventilation
NCT04542694 (12) [back to overview]	Rate of the Use of Non-invasive Lung Ventilation
NCT04542694 (12) [back to overview]	Rate of Transfer to the Intensive Care Unit
NCT04542694 (12) [back to overview]	Rate of Viral Elimination by Day 10
NCT04542694 (12) [back to overview]	The Number of Patients Achieved a Category Lower Than or Equal to 2 on the WHO Clinical Improvement Scale (They Were Discharged From Hospital)
NCT04542694 (12) [back to overview]	Time Before the End of Fever
NCT04542694 (12) [back to overview]	Time to Clinical Improvement
NCT04542694 (12) [back to overview]	Mortality
NCT04646109 (27) [back to overview]	Age Distribution of the Patients
NCT04646109 (27) [back to overview]	Body Temperature Means of the Patients
NCT04646109 (27) [back to overview]	Heart Rate Means of the Patients
NCT04646109 (27) [back to overview]	Mortality
NCT04646109 (27) [back to overview]	Number of Participants With Clinical Response
NCT04646109 (27) [back to overview]	Number of Participants With Clinical Response
NCT04646109 (27) [back to overview]	Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity
NCT04646109 (27) [back to overview]	Respiratory Rate Means of the Patients
NCT04646109 (27) [back to overview]	Treatment-Related Adverse Events as Assessed by CTCAE v4.0
NCT04646109 (27) [back to overview]	Changes in Oxygen Saturation (SpO2) Values
NCT04646109 (27) [back to overview]	Changes in Oxygen Saturation (SpO2) Values
NCT04646109 (27) [back to overview]	Changes in Serum D-dimer Levels
NCT04646109 (27) [back to overview]	Changes in Serum D-dimer Levels
NCT04646109 (27) [back to overview]	Changes in Serum Ferritin Levels
NCT04646109 (27) [back to overview]	Changes in Serum Ferritin Levels
NCT04646109 (27) [back to overview]	Changes in Serum Lymphocyte Counts
NCT04646109 (27) [back to overview]	Changes in Serum Lymphocyte Counts
NCT04646109 (27) [back to overview]	Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)
NCT04646109 (27) [back to overview]	Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)
NCT04646109 (27) [back to overview]	Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)
NCT04646109 (27) [back to overview]	Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)
NCT04646109 (27) [back to overview]	Gender Distribution of the Patients
NCT04646109 (27) [back to overview]	Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism
NCT04646109 (27) [back to overview]	Percentage of Patients With Accompanying Diseases
NCT04646109 (27) [back to overview]	Percentage of Patients With Baseline Clinical Symptoms
NCT04646109 (27) [back to overview]	Systolic and Diastolic Pressure Means of the Patients
NCT04646109 (27) [back to overview]	Treatment-Related Adverse Events as Assessed by CTCAE v4.0
NCT05502081 (53) [back to overview]	Alanine Aminotransferase (ALT) at Day 14
NCT05502081 (53) [back to overview]	Alanine Aminotransferase (ALT) at Day 28
NCT05502081 (53) [back to overview]	Alanine Aminotransferase (ALT) at Day 3
NCT05502081 (53) [back to overview]	Alanine Aminotransferase (ALT) at Day 7
NCT05502081 (53) [back to overview]	Albumin at Day 14
NCT05502081 (53) [back to overview]	Albumin at Day 28
NCT05502081 (53) [back to overview]	Albumin at Day 3
NCT05502081 (53) [back to overview]	Albumin at Day 7
NCT05502081 (53) [back to overview]	Creatine Kinase (Ck) at Day 3
NCT05502081 (53) [back to overview]	Creatine Kinase (Ck) at Day 7
NCT05502081 (53) [back to overview]	D-dimer at Day 14
NCT05502081 (53) [back to overview]	D-dimer at Day 28
NCT05502081 (53) [back to overview]	D-dimer at Day 3
NCT05502081 (53) [back to overview]	D-dimer at Day 7
NCT05502081 (53) [back to overview]	Day of Death
NCT05502081 (53) [back to overview]	Duration of Hospitalization
NCT05502081 (53) [back to overview]	Duration of Intensive Care Unit (ICU) Stay
NCT05502081 (53) [back to overview]	Ferritin at Day 14
NCT05502081 (53) [back to overview]	Ferritin at Day 28
NCT05502081 (53) [back to overview]	Ferritin at Day 3
NCT05502081 (53) [back to overview]	Ferritin at Day 7
NCT05502081 (53) [back to overview]	Lactate Dehydrogenase (LDH) at Day 14
NCT05502081 (53) [back to overview]	Lactate Dehydrogenase (LDH) at Day 28
NCT05502081 (53) [back to overview]	Lactate Dehydrogenase (LDH) at Day 3
NCT05502081 (53) [back to overview]	Aspartate Aminotransferase (AST) at Day 28
NCT05502081 (53) [back to overview]	Oxygen Support Duration (Days)
NCT05502081 (53) [back to overview]	Platelets at Day 14
NCT05502081 (53) [back to overview]	Platelets at Day 28
NCT05502081 (53) [back to overview]	Platelets at Day 3
NCT05502081 (53) [back to overview]	Platelets at Day 7
NCT05502081 (53) [back to overview]	Serum Creatinine (S.Cr) at Day 14
NCT05502081 (53) [back to overview]	Serum Creatinine (S.Cr) at Day 28
NCT05502081 (53) [back to overview]	Serum Creatinine (S.Cr) at Day 3
NCT05502081 (53) [back to overview]	Serum Creatinine (S.Cr) at Day 7
NCT05502081 (53) [back to overview]	Time to Clinical Improvement (Defined as 2 Points Reduction in the WHO Disease Ordinal Progression Scale or Discharge, Whatever Happens First
NCT05502081 (53) [back to overview]	Aspartate Aminotransferase (AST) at Day 7
NCT05502081 (53) [back to overview]	Bilirubin at Day 14
NCT05502081 (53) [back to overview]	Bilirubin at Day 28
NCT05502081 (53) [back to overview]	Aspartate Aminotransferase (AST) at Day 3
NCT05502081 (53) [back to overview]	Bilirubin at Day 3
NCT05502081 (53) [back to overview]	Bilirubin at Day 7
NCT05502081 (53) [back to overview]	C-reactive Protein (CRP) at Day 14
NCT05502081 (53) [back to overview]	C-reactive Protein (CRP) at Day 28
NCT05502081 (53) [back to overview]	C-reactive Protein (CRP) at Day 3
NCT05502081 (53) [back to overview]	C-reactive Protein (CRP) at Day 7
NCT05502081 (53) [back to overview]	Creatine Kinase (Ck) at Day 14
NCT05502081 (53) [back to overview]	Creatine Kinase (Ck) at Day 28
NCT05502081 (53) [back to overview]	Aspartate Aminotransferase (AST) at Day 14
NCT05502081 (53) [back to overview]	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7
NCT05502081 (53) [back to overview]	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3
NCT05502081 (53) [back to overview]	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 28
NCT05502081 (53) [back to overview]	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14
NCT05502081 (53) [back to overview]	Lactate Dehydrogenase (LDH) at Day 7

Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza

"Overall time required from first study drug administration to alleviation of the 6 primary influenza symptoms and for temperature (oral) measurements to be less than 38.0°C for patients aged 20 to less than 65 years and less than 37.8°C for patients aged 65 years or older. Alleviated was defined as all 6 symptom scores had to be decreased to 1 or below and the decrease remain unchanged for 21.5 hours." (NCT01068912)
Timeframe: 22 weeks

Intervention	hours (Median)
1: Low Dose Favipiravir	100.4
2: High Dose Favipiravir	86.5
Placebo	91.9

Intervention	cycles (Median)
	Day 1	Day 5	Day 10	Day 28
Favipiravir	22.2	27.9	40.0	40.0
Placebo	25.1	27.3	37.3	40.0

Intervention	days (Median)
	Initial resolution of symptoms	Sustained resolution of symptoms
Favipiravir	15	NA
Placebo	14	24

Intervention	µg/mL (Median)
	Day 1	Day 2	Day 8	Day 14
Favipiravir Treatment Arm	3.24	8.19	17.1	15.5

Intervention	ng*hr/mL (Least Squares Mean)
FAVIRA (Novelfarma-Turkey)	10400.038
AVIGAN (Toyama-Japan)	9907.948

Intervention	ng/mL (Least Squares Mean)
FAVIRA (Novelfarma-Turkey)	5242.459
AVIGAN (Toyama-Japan)	4969.881

Intervention	percentage of peripheral capillary O2 (Mean)
	Baseline	TD1	TD3	TD5
Control Group	89.67	90.50	91.90	93.00
Study Group	89.93	92.85	93.07	93.52

Intervention	mg/L (Mean)
	Baseline	TD1	TD3	TD5
Control Group	1.32	2.80	4.14	3.58
Study Group	1.25	1.40	3.24	5.85

Intervention	mg/dL (Mean)
	Baseline	TD1	TD3	TD5
Control Group	747.05	783.03	881.17	1028.24
Study Group	682.75	834.94	875.90	875.12

Intervention	cell/mm^3 (Mean)
	Baseline	TD1	TD3	TD5
Control Group	1010	1034	977	968
Study Group	932	928	1021	1273

Intervention	Ratio (Mean)
	Baseline	TD1	TD3	TD5
Control Group	197.44	181.83	174.77	180.13
Study Group	158.83	147.31	147.74	178.94

Intervention	Ratio (Mean)
	Baseline	TD1	TD3	TD5
Control Group	7.48	7.74	9.26	9.88
Study Group	8.77	10.82	9.02	7.16

Intervention	Participants (Count of Participants)
	Mutation positive	Mutation negative
Control Group	0	0
Study Group	6	30

Intervention	Participants (Count of Participants)
	Diabetes Mellitus	Hypertension	Coronary artery disease	Cardiac failure	Chronic obstructive pulmonary disease	Malignancy	Immunodeficiency
Control Group	10	12	8	1	3	1	1
Study Group	9	15	5	0	6	0	0

Intervention	Participants (Count of Participants)
	Fever	Cough	Sore throat	dyspnea	Headache	Weakness	Myalgia	Diarrhea	Nausea or vomiting
Control Group	13	14	1	19	2	11	7	0	0
Study Group	15	16	3	23	5	13	9	1	1

Intervention	mmHg (Mean)
	Systolic pressure	Diastolic pressure
Control Group	124.61	73.43
Study Group	124.39	75.64

Intervention	Participants (Count of Participants)
	Nausea and vomiting	Increase in liver function tests
Control Group	2	1
Study Group	0	0

Intervention	Units/liter (Mean)
Casirivimab and Imdevimab	15.75
Remdesivir	22.42
Favipravir	35.38

Intervention	Units/liter (Mean)
Casirivimab and Imdevimab	33.62
Remdesivir	36.46
Favipravir	36.16

Intervention	gm/dl (Mean)
Casirivimab and Imdevimab	3.157
Remdesivir	2.947
Favipravir	2.854

Intervention	Units/liter (Mean)
Casirivimab and Imdevimab	142.2
Remdesivir	197.94
Favipravir	181.45

favipiravir

Description

Cross-References

Synonyms (76)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Pathways (1)

Bioassays (542)

Research

Studies (590)

Market Indicators

Research Demand Index: 74.61

Study Types

Clinical Trials (69)

Trial Overview

Trial Outcomes

Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza

Count of Participant With Absence of Development of Any Symptoms

Time Until Cessation of Oral Shedding of SARS-CoV-2 Virus

Count of Participants With Clinical Worsening of COVID-19 Disease

Count of Participants With Development of SARS-CoV-2 Antibodies

Sars-CoV-2 Viral Load

Time Until Cessation of Symptoms

Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmin

Time to the National Early Warning Score 2 (NEWS2) of 2 or Less, or Hospital Discharge

Time to Viral Clearance

Characterize the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmax

Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Area Under Curve (AUC 0-24)

AUC0-tlast

Favipiravir Cmax

Tmax of Favipiravir

AUC0-inf of Favipiravir

Tmax of Favipiravir

Cmax of Favipiravir

AUC0-tlast of Favipiravir

AUC0-inf of Favipiravir

Primary Efficacy Endpoint: Time to Resolution of Hypoxia (Stage I)

Percentage of Patients Dying (All Cause (Stage I)

A Number of Patients With Fever Reduction Below 37.2 ° C by the 3rd Day of Therapy

Amount of Patients Without Any Clinical Signs of Disease by the Completion of Therapy (Category 0 According to a WHO Categorical Ordinal Scale)

Change in the Level of Lung Damage According to CT

Rate of Clinical Status Improvement

Rate of the Use of Mechanical Ventilation

Rate of the Use of Non-invasive Lung Ventilation

Rate of Transfer to the Intensive Care Unit

Rate of Viral Elimination by Day 10

The Number of Patients Achieved a Category Lower Than or Equal to 2 on the WHO Clinical Improvement Scale (They Were Discharged From Hospital)

Time Before the End of Fever

Time to Clinical Improvement

Mortality

Age Distribution of the Patients

Body Temperature Means of the Patients

Heart Rate Means of the Patients

Mortality

Number of Participants With Clinical Response

Number of Participants With Clinical Response

Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity

Respiratory Rate Means of the Patients

Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Changes in Oxygen Saturation (SpO2) Values

Changes in Oxygen Saturation (SpO2) Values

Changes in Serum D-dimer Levels

Changes in Serum D-dimer Levels

Changes in Serum Ferritin Levels

Changes in Serum Ferritin Levels

Changes in Serum Lymphocyte Counts

Changes in Serum Lymphocyte Counts

Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)

Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)

Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)

Intervention	Units/liter (Mean)
Casirivimab and Imdevimab	126.743
Remdesivir	211.9
Favipravir	175.99

Intervention	μg/mL (Mean)
Casirivimab and Imdevimab	0.109
Remdesivir	0.319
Favipravir	0.425

Intervention	micrograms per liter (Mean)
Casirivimab and Imdevimab	398.5
Remdesivir	637.37
Favipravir	519.88

Intervention	micrograms per liter (Mean)
Casirivimab and Imdevimab	393.04
Remdesivir	427.25
Favipravir	1110

Intervention	micrograms per liter (Mean)
Casirivimab and Imdevimab	368.42
Remdesivir	450.37
Favipravir	1433

Intervention	international units per liter (Mean)
Casirivimab and Imdevimab	379.75
Remdesivir	360.89
Favipravir	306.88

Intervention	international units per liter (Mean)
Casirivimab and Imdevimab	351.27
Remdesivir	404.45
Favipravir	354.7

Intervention	10^3 cells/uL (Mean)
Casirivimab and Imdevimab	248
Remdesivir	216.95
Favipravir	215.63

Intervention	10^3 cells/uL (Mean)
Casirivimab and Imdevimab	271.64
Remdesivir	253.425
Favipravir	226.35

Intervention	10^3 cells/uL (Mean)
Casirivimab and Imdevimab	268.829
Remdesivir	243.514
Favipravir	212.76